Passage Bio Stock Performance
| PASG Stock | USD 19.85 1.52 8.29% |
Passage Bio holds a performance score of 16 on a scale of zero to a hundred. The company holds a Beta of 4.95, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Passage Bio will likely underperform. Use Passage Bio expected short fall, and the relationship between the value at risk and daily balance of power , to analyze future returns on Passage Bio.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Passage Bio are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Passage Bio reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 8.29 | Five Day Return 49.02 | Year To Date Return 69.8 | Ten Year Return (95.53) | All Time Return (95.53) |
Last Split Factor 1:20 | Last Split Date 2025-07-14 |
1 | Disposition of 30000 shares by Kathleen Borthwick of Passage Bio subject to Rule 16b-3 | 10/15/2025 |
2 | Why Passage Bio Inc. stock remains a top recommendation - Trend Reversal High Conviction Trade Alerts - newser.com | 10/30/2025 |
3 | Why Passage Bio Inc. is moving today - July 2025 Trade Ideas Long-Term Growth Portfolio Plans - newser.com | 11/03/2025 |
4 | Is Passage Bio Inc. stock bottoming out - Trade Entry Report Step-by-Step Swing Trade Plans - newser.com | 11/07/2025 |
5 | Passage Bio Issues Quarterly Earnings Results | 11/12/2025 |
6 | Risk Off Will Passage Bio Inc. stock sustain high P E ratios - Quarterly Portfolio Report Free Technical Confirmation Trade Alerts - B NI V | 11/26/2025 |
7 | Passage Bio Inc Stock Analysis and Forecast - Institutional Buying Trends Capitalize On Fast Trends - earlytimes.in | 12/03/2025 |
8 | Critical Analysis Passage Bio Vir Biotechnology | 12/24/2025 |
9 | Passage Bio Trading Down 2.3 percent - Heres What Happened - MarketBeat | 01/07/2026 |
| Begin Period Cash Flow | 21.7 M | |
| Total Cashflows From Investing Activities | 54.9 M |
Passage Bio Relative Risk vs. Return Landscape
If you would invest 869.00 in Passage Bio on October 13, 2025 and sell it today you would earn a total of 1,116 from holding Passage Bio or generate 128.42% return on investment over 90 days. Passage Bio is currently generating 1.5867% in daily expected returns and assumes 7.7193% risk (volatility on return distribution) over the 90 days horizon. In different words, 69% of stocks are less volatile than Passage, and 69% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Passage Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Passage Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Passage Bio, and traders can use it to determine the average amount a Passage Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2056
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | PASG | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Passage Bio is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Passage Bio by adding it to a well-diversified portfolio.
Passage Bio Fundamentals Growth
Passage Stock prices reflect investors' perceptions of the future prospects and financial health of Passage Bio, and Passage Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Passage Stock performance.
| Return On Equity | -0.87 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | 34.66 M | ||||
| Shares Outstanding | 3.18 M | ||||
| Price To Book | 2.03 X | ||||
| EBITDA | (62.09 M) | ||||
| Net Income | (64.77 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 25.48 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.23 X | ||||
| Book Value Per Share | 9.79 X | ||||
| Cash Flow From Operations | (47.96 M) | ||||
| Earnings Per Share | (14.62) X | ||||
| Market Capitalization | 63.1 M | ||||
| Total Asset | 102.41 M | ||||
| Retained Earnings | (659.24 M) | ||||
| Working Capital | 59.45 M | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
About Passage Bio Performance
By analyzing Passage Bio's fundamental ratios, stakeholders can gain valuable insights into Passage Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Passage Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Passage Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.73) | (0.76) | |
| Return On Capital Employed | (0.97) | (1.02) | |
| Return On Assets | (0.73) | (0.76) | |
| Return On Equity | (1.22) | (1.16) |
Things to note about Passage Bio performance evaluation
Checking the ongoing alerts about Passage Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Passage Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Passage Bio is way too risky over 90 days horizon | |
| Passage Bio appears to be risky and price may revert if volatility continues | |
| Passage Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (64.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Passage Bio currently holds about 239.25 M in cash with (47.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39. | |
| Latest headline from MacroaxisInsider: Acquisition by Felix Lourdes of 25000 shares of Lixte Biotechnology at 4.05 subject to Rule 16b-3 |
- Analyzing Passage Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Passage Bio's stock is overvalued or undervalued compared to its peers.
- Examining Passage Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Passage Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Passage Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Passage Bio's stock. These opinions can provide insight into Passage Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |